abstract |
The invention relates to the CGRP antagonists of general formula (I) in which R1, R2, R3 and R4 are defined as in claim 1, to their tautomers, isomers, diastereoisomers and enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, as well as to the compounds of general formula (I) in which one or more hydrogen atoms are exchanged for deuterium, to medicaments containing these compounds, the use thereof and to methods for the production thereof. |